Compare AbCellera Biologics Inc (ABCL) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs QUALCOMM, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while QUALCOMM, Inc. trades at $187.2 (market cap $192.85B). The key difference: QUALCOMM, Inc. is far larger — about 82.1× AbCellera Biologics Inc's market cap, and QUALCOMM, Inc. pays a 2.01% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | QCOM | |
|---|---|---|
Market Cap | $2.35B | $192.85B |
Sector | Health | Technology |
52-Week High | $8.12 | $251.10 |
52-Week Low | $2.78 | $124.07 |
Enterprise Value | $1.99B | $198.32B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Qualcomm (QCOM) trades at $186.52, up 0.02% on the day, with a bearish technical signal and key support at $180. The company reported strong recent earnings beats, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Revenue for 2025 reached $44.28B, though net income margin declined to 12.51%. Analyst consensus is a Buy with a $221.21 price target, while recent news highlights competitive pressures from Nvidia's entry into the PC chip market.
The outlook for QCOM is mixed; diversification into AI and automotive offers growth, but smartphone market softness and margin pressures pose near-term risks. Valuation metrics like a P/E of 19.67 and ROE of 29.27% suggest solid fundamentals, yet investors face volatility from intense semiconductor competition and cyclical demand swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
